Font Size:
Biogen Idec Expands its Portfolio with ALS Drug Candidate
Heather Cartwright
Abstract
Biogen Idec has signed an exclusive licensing deal with Knopp Neurosciences, potentially worth US$345 M, for a Phase II drug candidate for the treatment of amyotrophic lateral sclerosis.
Add comment
This work is licensed under a Creative Commons Attribution 3.0 License.